Alaunos Therapeutics (TCRT) Change in Cash (2009 - 2026)

Alaunos Therapeutics has reported Change in Cash for 18 years, with the latest figure at -$1.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash fell 33.55% year-over-year to -$1.0 million; the trailing twelve-month figure through Mar 2026 stood at $35000.0 (up 100.91% YoY), and the FY2025 full-year result was $294000.0, up 105.91% from the prior year.
• Change in Cash for Q1 2026 stood at -$1.0 million, down from -$553000.0 in the prior quarter.
• The five-year high for Change in Cash was $2.6 million in Q2 2025, with the low at -$19.1 million in Q2 2023.
• Historically, Change in Cash has averaged -$4.5 million across 5 years, with a median of -$1.7 million in 2024.
• Annual changes were most pronounced in 2023 — Change in Cash plunged 570.18% — and 2025, when it soared 252.29%.
• Alaunos Therapeutics' Change in Cash stood at $1.3 million in 2022, then sank by 570.18% to -$5.9 million in 2023, then jumped by 89.94% to -$592000.0 in 2024, then advanced by 6.59% to -$553000.0 in 2025, then plunged by 86.44% to -$1.0 million in 2026.
• The last three Change in Cash figures came in at -$1.0 million (Q1 2026), -$553000.0 (Q4 2025), and -$941000.0 (Q3 2025), per Business Quant data.